Drugs / alfa-2b
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00996216 Background | Sep 2009 → Feb 2013 | hepatitis C virus infection | GlaxoSmithKline | Completed | No outcome recorded |
Press releases naming this drug 13 releases
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | alfa-2b | “Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.” NCT00996216 ↗ |